A New Pancreatic Cancer Pill Nearly Doubled Median Survival—Now the FDA Has Approved It
No Comments on A New Pancreatic Cancer Pill Nearly Doubled Median Survival—Now the FDA Has Approved It
August 27, 2026
The FDA has approved daraxonrasib, a once-daily targeted pill that delivered 13.2 months of median survival versus 6.7 months with chemotherapy in a 500-patient trial.